Stock Review for Biotech's Investors -- Cyclacel Pharma, Capricor Therapeutics, Cymabay Therapeutics, and BioDelivery Sciences

Monday, December 11, 2017 Drug News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, December 11, 2017 /PRNewswire/ --

In keeping with the commitment to dynamically provide members with timely

information, WallStEquities.com has issued free tailored Stock Review on CYCC, CAPR, CBAY, and BDSI which is a click away at www.wallstequities.com/registration. On Friday, December 08, 2017, the NASDAQ Composite ended
the trading session at 6,840.08, up 0.40%; the Dow Jones Industrial Average edged 0.49% higher, to finish at 24,329.16; and the S&P 500 closed at 2,651.50, slightly advancing 0.55%. Gains were broad based as eight out of nine sectors ended the day in positive. This Monday, WallStEquities.com has initiated reports coverage on the following Biotechnology equities: Cyclacel Pharmaceuticals Inc. (NASDAQ: CYCC), Capricor Therapeutics Inc. (NASDAQ: CAPR), Cymabay Therapeutics Inc. (NASDAQ: CBAY), and BioDelivery Sciences International Inc. (NASDAQ: BDSI). Sign up today for free and learn why our members refer to our research coverage as the 'best out there':

www.wallstequities.com/registration

Cyclacel Pharmaceuticals 

Berkeley Heights, New Jersey headquartered Cyclacel Pharmaceuticals Inc.'s stock finished Friday's session 9.29% higher at $2.00 with a total trading volume of 2.49 million shares, which was above its three months average volume of 816.64 thousand shares. The Company's shares have advanced 25.79% in the last month and 19.76% in the previous three months. The stock is trading above its 50-day moving average by 9.45%. Additionally, shares of Cyclacel Pharma, which develops medicines for the treatment of cancer and other proliferative diseases, have a Relative Strength Index (RSI) of 56.35. Signing up now gives you access to the free research coverage on CYCC at:

www.wallstequities.com/registration/?symbol=CYCC

Capricor Therapeutics 

On Friday, shares in Beverly Hills, California headquartered Capricor Therapeutics Inc. recorded a trading volume of 152,765 shares. The stock ended the session 1.67% lower at $1.77. The Company's shares have advanced 73.53% in the previous three months. The stock is trading below its 50-day and moving average by 24.79%. Moreover, shares of Capricor Therapeutics, which focuses on the discovery, development, and commercialization of novel therapeutics primarily for the treatment of cardiovascular diseases, have an RSI of 34.78. Get access to our top-rated research, including the free report on CAPR at: www.wallstequities.com/registration/?symbol=CAPR

Cymabay Therapeutics 

Newark, California headquartered Cymabay Therapeutics Inc.'s shares closed the day 0.73% higher at $8.33. The stock recorded a trading volume of 529,060 shares. The Company's shares have gained 32.85% over the previous three months, 390.00% over the last twelve months, and 381.50% since the start of the year. The stock is trading above its 200-day moving average by 38.47%. Additionally, shares of Cymabay Therapeutics, which focuses on developing and commercializing therapies to treat specialty and orphan diseases, have an RSI of 44.33. Click here to subscribe for a free membership which welcomes you with our report on CBAY at:

www.wallstequities.com/registration/?symbol=CBAY

BioDelivery Sciences International 

Shares in Raleigh, North Carolina headquartered BioDelivery Sciences International Inc. finished 1.82% higher at $2.80. The stock recorded a trading volume of 709,140 shares, which is above its three months average volume of 585.19 thousand shares. The Company's shares have advanced 75.00% over the last twelve months and 60.00% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 1.58% and 10.30%, respectively. Furthermore, shares of the Company, which engages in the development and commercialization of pharmaceutical products principally in the areas of pain management and addiction, have an RSI of 59.75. Join our big investor community at Wall St. Equities today and start so with your free report on BDSI at:

www.wallstequities.com/registration/?symbol=BDSI

--

Wall St. Equities: 

Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

WSE has not been compensated; directly or indirectly; for producing or publishing this document. 

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@wallstequities.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  

NO WARRANTY 

WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 

NOT AN OFFERING 

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

https://wallstequities.com/legal-disclaimer/

CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: info@wallstequities.com Phone number: +21-32-044-483 Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228 CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Wall St. Equities

Advertisement


Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store